Eli Lilly and Company (NYSE:LLY) Short Interest Update

Eli Lilly and Company (NYSE:LLYGet Rating) saw a large increase in short interest in the month of August. As of August 31st, there was short interest totalling 5,180,000 shares, an increase of 7.5% from the August 15th total of 4,820,000 shares. Approximately 0.7% of the shares of the company are short sold. Based on an average daily volume of 2,620,000 shares, the days-to-cover ratio is presently 2.0 days.

Insider Activity at Eli Lilly and

In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction on Friday, June 24th. The stock was sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the sale, the insider now directly owns 104,203,810 shares in the company, valued at approximately $33,794,337,621.10. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction on Friday, June 24th. The stock was sold at an average price of $324.31, for a total transaction of $69,726,650.00. Following the sale, the insider now directly owns 104,203,810 shares in the company, valued at approximately $33,794,337,621.10. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jackson P. Tai bought 656 shares of Eli Lilly and stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average price of $304.19 per share, with a total value of $199,548.64. Following the completion of the transaction, the director now owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The disclosure for this purchase can be found here. In the last three months, insiders have sold 543,125 shares of company stock worth $178,307,801. 0.12% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and

Several institutional investors have recently bought and sold shares of LLY. Federated Hermes Inc. raised its position in Eli Lilly and by 122.0% during the 2nd quarter. Federated Hermes Inc. now owns 114,005 shares of the company’s stock valued at $36,964,000 after purchasing an additional 62,661 shares during the last quarter. Private Trust Co. NA raised its position in Eli Lilly and by 4.2% during the 2nd quarter. Private Trust Co. NA now owns 10,257 shares of the company’s stock valued at $3,326,000 after purchasing an additional 410 shares during the last quarter. Brown Advisory Inc. raised its position in Eli Lilly and by 8.7% during the 2nd quarter. Brown Advisory Inc. now owns 97,992 shares of the company’s stock valued at $31,772,000 after purchasing an additional 7,850 shares during the last quarter. Royal London Asset Management Ltd. raised its position in Eli Lilly and by 12.2% during the 2nd quarter. Royal London Asset Management Ltd. now owns 938,889 shares of the company’s stock valued at $304,721,000 after purchasing an additional 102,433 shares during the last quarter. Finally, Amundi raised its position in Eli Lilly and by 0.9% during the 2nd quarter. Amundi now owns 3,766,227 shares of the company’s stock valued at $1,230,725,000 after purchasing an additional 34,190 shares during the last quarter. 82.45% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Trading Down 1.1 %

Shares of LLY stock opened at $301.73 on Wednesday. The stock has a market capitalization of $286.69 billion, a PE ratio of 48.12, a P/E/G ratio of 1.97 and a beta of 0.38. Eli Lilly and has a 1-year low of $220.20 and a 1-year high of $335.33. The business has a 50-day moving average of $315.61 and a 200 day moving average of $304.18. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85.

Eli Lilly and (NYSE:LLYGet Rating) last issued its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.86 by ($0.61). The company had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The company’s revenue was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.87 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and will post 7.97 earnings per share for the current year.

Eli Lilly and Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 9th. Investors of record on Monday, August 15th were issued a dividend of $0.98 per share. This represents a $3.92 annualized dividend and a yield of 1.30%. The ex-dividend date of this dividend was Friday, August 12th. Eli Lilly and’s dividend payout ratio is presently 62.52%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on LLY shares. BMO Capital Markets boosted their target price on Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 6th. Barclays boosted their target price on Eli Lilly and from $333.00 to $355.00 and gave the stock an “overweight” rating in a research report on Thursday, July 7th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. StockNews.com upgraded Eli Lilly and from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 14th. Finally, Morgan Stanley upped their price objective on Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a report on Wednesday, September 7th. Three research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $330.44.

About Eli Lilly and

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.